# Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome

> **NCT05250245** · PHASE4 · COMPLETED · sponsor: **Yuzuncu Yil University** · enrollment: 60 (actual)

## Conditions studied

- Overactive Bladder
- Obstructive Sleep Apnea
- Overactive Bladder Syndrome

## Interventions

- **DRUG:** Tolterodine Tartrate 4 MG
- **OTHER:** Continuous positive airway pressure therapy (CPAP)

## Key facts

- **NCT ID:** NCT05250245
- **Lead sponsor:** Yuzuncu Yil University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-01-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250245, "Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05250245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*